Cite
Impact of Myc-Altered Pathology on Radiotherapy Efficacy among Patients with Relapsed/Refractory Large-B Cell Lymphoma: A Collaborative Retrospective Study.
MLA
Tseng, Y. D., et al. “Impact of Myc-Altered Pathology on Radiotherapy Efficacy among Patients with Relapsed/Refractory Large-B Cell Lymphoma: A Collaborative Retrospective Study.” International Journal of Radiation Oncology, Biology, Physics, vol. 114, no. 3, Nov. 2022, pp. S55–56. EBSCOhost, https://doi.org/10.1016/j.ijrobp.2022.07.435.
APA
Tseng, Y. D., Stevenson, P., Lee, D. Y., Paydar, I., Kim, A., Ravella, R., Barbour, A. B., Ababneh, H., Binkley, M. S., Lo, A. C., Dedeckova, K., Hoppe, R. T., Ballas, L. K., Patel, C. G., Kelsey, C. R., Jr, K. A. K., Balogh, A., & Plastaras, J. P. (2022). Impact of Myc-Altered Pathology on Radiotherapy Efficacy among Patients with Relapsed/Refractory Large-B Cell Lymphoma: A Collaborative Retrospective Study. International Journal of Radiation Oncology, Biology, Physics, 114(3), S55–S56. https://doi.org/10.1016/j.ijrobp.2022.07.435
Chicago
Tseng, Y.D., P. Stevenson, D.Y. Lee, I. Paydar, A. Kim, R. Ravella, A.B. Barbour, et al. 2022. “Impact of Myc-Altered Pathology on Radiotherapy Efficacy among Patients with Relapsed/Refractory Large-B Cell Lymphoma: A Collaborative Retrospective Study.” International Journal of Radiation Oncology, Biology, Physics 114 (3): S55–56. doi:10.1016/j.ijrobp.2022.07.435.